Lombard, Aurélie
Mistry, Hitesh
Chapman, Sonya C.
Gueoguieva, Ivelina
Aarons, Leon
Ogungbenro, Kayode
Funding for this research was provided by:
Centre for Applied Pharmacokinetic Research Division of Pharmacy and Optometry University of Manchester (-)
Article History
Received: 10 December 2019
Accepted: 27 February 2020
First Online: 13 March 2020
Compliance with ethical standards
:
: SCC and IG are employees and shareholders of Eli Lilly & Company at the time the work was done. AL is a PhD student sponsored by the Centre for Applied Pharmacokinetic Research (CAPKR) and the Division of Pharmacy and Optometry, University of Manchester (CAPKR is supported by the following consortium members; AbbVie, Eli Lilly, Certara, Merck, Genentech, GlaxoSmithKline, Takeda Pharmaceuticals, Janssen, Merck Sharp and Dohme). KO and LA are members of CAPKR.
: The protocol for the study was approved by the Institutional Ethics Board. The study was conducted in accordance with the Declaration of Helsinki.
: Informed consent was obtained from all patients prior to enrolment in the study.